Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Motif Bio
London, United Kingdom
- Ownership
- Private
- Development stage
- Other
01
Overview
Motif Bio was developing iclaprim, a novel diaminopyrimidine antibiotic for serious Gram-positive bacterial infections (especially those resistant to other antibiotics); completed Phase 3 trials but did not achieve FDA approval and ceased R&D operations.
- Therapeutic areas
- Infectious Diseases
- Modalities
- Small moleculeantibiotics
- Industry
- Biotech
02
Partnerships
No major pharmaceutical partnerships reported; the company attempted to commercialize its lead asset independently, with some clinical collaborations
Beyond the preview
Go deeper on Motif Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Motif Bio.